Form 4: Spyre Therapeutics Insider Sells Shares Under 10b5-1 Plan

Spyre Therapeutics CEO Cameron Turtle sold company stock valued at approximately $607,000 through a pre-arranged trading plan.

Summary

• Cameron Turtle, CEO of Spyre Therapeutics, Inc. (SYRE), reported transactions involving the sale of common stock.
• These sales occurred on April 1, 2026, and were executed under a Rule 10b5-1 trading plan established on June 20, 2025.
• A total of 12,344 shares were sold at a weighted average price of $49.20, resulting in a disposition of approximately $607,000.
• An additional 2,656 shares were sold at a weighted average price of $49.92.
• Following these transactions, Turtle beneficially owns 627,540 shares of common stock.
• The reported holdings include 116,168 shares that vest in monthly installments through November 2026, contingent on continued employment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sales were conducted under a pre-established 10b5-1 plan, which is a standard practice for insider stock transactions.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-trading-related sales.
• The CEO continues to hold a significant number of shares (627,540) after the reported sales.
• A portion of the CEO's holdings (116,168 shares) are subject to vesting, aligning future incentives with continued service.

Negatives

• The CEO sold a notable number of shares, which could be perceived negatively by the market.
• The sales represent a reduction in the CEO's direct beneficial ownership.

Risks

• The sales, even if under a 10b5-1 plan, could be interpreted by the market as a lack of confidence by management in future stock performance.
• Vesting shares are subject to continued service, implying a risk of forfeiture if employment is terminated before vesting dates.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common and often reflect personal financial planning rather than a view on the company's future. However, the volume and timing relative to company news can influence market perception.

Stakeholder Impact

• Shareholders: May perceive insider sales as a negative signal, although the 10b5-1 plan mitigates this concern to some extent. The continued significant ownership by the CEO may be viewed positively.
• Employees: The vesting schedule for the CEO's shares aligns their incentives with continued employment, potentially benefiting employees through leadership stability.
• Management: The use of a 10b5-1 plan demonstrates adherence to corporate governance best practices regarding insider trading.

Next Steps

• The Reporting Person will provide detailed pricing information upon request from the SEC, Issuer, or security holders.
• Monthly vesting of 116,168 shares will continue through November 2026, subject to continued service.

Key Dates

Recommendation

The filing reports routine stock sales by the CEO under a pre-arranged 10b5-1 plan. While insider selling can be a concern, the structured nature of these transactions and the CEO's substantial remaining beneficial ownership suggest this is likely for personal financial management rather than a negative outlook on the company. Therefore, a 'hold' recommendation is appropriate, pending further company-specific developments.

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, CEO, Cameron Turtle, SEC Filing